Metropolis Healthcare Ltd — Q1 FY27 earnings call
Summary generated by AI from the official transcript Metropolis Healthcare Ltd filed with BSE on 10 Aug 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Metropolis Healthcare reported Q1 FY27 revenue growth of approximately 17% year-on-year to Rs 450 crores, driven primarily by volume growth, with EBITDA margin expanding 210 basis points to 25.2%. Patient volumes grew 10% and test volumes grew 11%, with no price increases taken over the last 18 months. Management discussed integration progress on Core Diagnostics, network expansion in Tier-2 and Tier-3 towns, and performance across B2C, B2B, Specialty and TruHealth segments.
Numbers mentioned
Revenue: INR 450 crores (Q1 FY27)
p. 7
“Revenue grew by about 17% year-on-year to INR 450 crores, ahead of our stated guidance, while EBITDA margin expanded by 210 basis points to 25.2%.”
Surendran Chemmenkotil, page 7 of the filed PDF · View the filing
EBITDA margin: 25.2% (Q1 FY27)
p. 10
“EBITDA margin expanded to 25.2%, an improvement of 210 basis points year-on-year and ahead of our guidance.”
Surendran Chemmenkotil, page 10 of the filed PDF · View the filing
Patient volume growth: 10% (Q1 FY27)
p. 10
“Revenue stood at INR 450 crores, registering growth of 17% year-on-year, supported by 10% growth in patient volume and 11% growth in test volume.”
Sameer Patel, page 10 of the filed PDF · View the filing
EBITDA: INR 113 crores (Q1 FY27)
p. 11
“Q1 EBITDA stood at INR 113 crores, growing 27% year-on-year.”
Sameer Patel, page 11 of the filed PDF · View the filing
PAT: INR 57 crores (Q1 FY27)
p. 11
“Q1 PAT stood at INR 57 crores, growing at 26% year-on-year.”
Sameer Patel, page 11 of the filed PDF · View the filing
PAT margin: 12.6% (Q1 FY27)
p. 11
“PAT margin expanded by 90 basis points to 12.6%.”
Sameer Patel, page 11 of the filed PDF · View the filing
B2C revenue growth: 18% (Q1 FY27)
p. 7
“B2C grew by 18%, and B2B grew by 15%.”
Surendran Chemmenkotil, page 7 of the filed PDF · View the filing
North India revenue contribution: 18% (Q1 FY27)
p. 6
“As a result, North India now contributes 18% of the company's revenue, up from a single-digit contribution before the acquisition and has emerged as the fastest-growing region in our network.”
Ameera Shah, page 6 of the filed PDF · View the filing
Specialty Diagnostics contribution to revenue: 40% (Q1 FY27)
p. 11
“Specialty contributed 40% of revenue, grew 17% year-on-year.”
Sameer Patel, page 11 of the filed PDF · View the filing
TruHealth contribution to revenue: 18% (Q1 FY27)
p. 11
“TruHealth contributed 18% of Quarter 1 FY 2027 revenue and grew 22% year-on-year.”
Sameer Patel, page 11 of the filed PDF · View the filing
Center-to-laboratory ratio: 1:24 (Q1 FY27)
p. 8
“Our centerto-laboratory ratio improved from 1:21 a year ago to 1:24 in Quarter 1, and we remain on track to improve this to around 1:30 by year-end, creating meaningful operating leverage as utilization continues to improve.”
Surendran Chemmenkotil, page 8 of the filed PDF · View the filing
Core Diagnostics margin: high single-digit margin (Q1 FY27)
p. 20
“and this quarter we are high single-digit margin from the Core Diagnostics business.”
Surendran Chemmenkotil, page 20 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Revenue growth — 14%-15% · FY27
stated firmly by Ameera Shah
p. 5
“We believe this is a good start to our year and that we can sustain revenue growth outlook of 14%-15% for the year, which we expect to be primarily driven by volume growth.”
Ameera Shah, page 5 of the filed PDF · View the filing
EBITDA margin improvement — 100-150 basis points · current financial year
stated firmly by Ameera Shah
p. 5
“Supported by ongoing operational efficiencies and cost optimization initiatives, we expect an improvement of 100-150 basis points on EBITDA during the current financial year and over this year and the next year, we remain focused on achieving an EBITDA margin of 27%-28%.”
Ameera Shah, page 5 of the filed PDF · View the filing
Center additions in Tier-2 and Tier-3 towns — approximately 400-500 centers · this year
stated as an aspiration by Ameera Shah
p. 6
“We aim to open approximately 400-500 centers in Tier-2 and Tier-3 towns this year.”
Ameera Shah, page 6 of the filed PDF · View the filing
Specialty Diagnostics portfolio contribution — 45%
stated as an aspiration by Ameera Shah
p. 7
“We aim to increase contribution of this portfolio to 45% from the current 40%.”
Ameera Shah, page 7 of the filed PDF · View the filing
Center-to-laboratory ratio — around 1:30 · by year-end
stated firmly by Surendran Chemmenkotil
p. 8
“we remain on track to improve this to around 1:30 by year-end, creating meaningful operating leverage as utilization continues to improve.”
Surendran Chemmenkotil, page 8 of the filed PDF · View the filing
Core Diagnostics EBITDA margin — around 25% · 3-4 years from acquisition
stated firmly by Ameera Shah
p. 6
“with a clear plan to transform it into a business capable of delivering EBITDA margins of around 25% over 3-4 years from acquisition.”
Ameera Shah, page 6 of the filed PDF · View the filing
Revenue growth CAGR — 14%-15% · medium-term
stated firmly by Surendran Chemmenkotil
p. 13
“We continue to maintain that our medium-term CAGR guidance is about 14%-15%.”
Surendran Chemmenkotil, page 13 of the filed PDF · View the filing
Patient volume growth contribution to revenue growth — 9%-10%
stated firmly by Surendran Chemmenkotil
p. 13
“Out of this 14%-15%, about 9%-10% will come from patient volume growth, and the remaining will come from the product mix.”
Surendran Chemmenkotil, page 13 of the filed PDF · View the filing
Net center additions — more than 500 centers · current financial year
stated firmly by Surendran Chemmenkotil
p. 8
“and remain on track to add more than 500 centers during the current financial year.”
Surendran Chemmenkotil, page 8 of the filed PDF · View the filing
CAPEX — similar to INR 65 crores · this year
stated firmly by Surendran Chemmenkotil
p. 19
“As far as the CAPEX is concerned, I think last year we did INR 65 crores of CAPEX and I think our CAPEX requirement for this year will also be in the similar lines.”
Surendran Chemmenkotil, page 19 of the filed PDF · View the filing
Price increase — near future
stated conditionally by Surendran Chemmenkotil
p. 15
“In the near future, we are not contemplating a price increase at this stage. At the right appropriate opportunity, whenever the market is conducive to absorb a little more on the price, we will definitely would like to do that.”
Surendran Chemmenkotil, page 15 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
B2C patient volume growth was about 13.5% and B2B patient volume growth was about 6%.
Answered by Surendran Chemmenkotil
Asked by Tausif Shaikh: What is the split of patient volume growth between B2B and B2C for the quarter?
p. 11
“The B2C patient volume growth is about 13.5%, and B2B patient volume growth is about 6%. That's the split of B2B and B2C.”
Surendran Chemmenkotil, page 11 of the filed PDF · View the filing
CGHS is about a percentage or so of total business, so the price increase did not provide a significant benefit compared to peers.
Answered by Surendran Chemmenkotil
Asked by Surya Patra: What portion of the business is CGHS and has the company seen benefit from the CGHS price revision?
p. 13
“Our contribution of CGHS to the overall business was almost about a percentage or so and hence, we are not getting a huge bump up on the CGHS price increase but whatever you get it out of that small business we have, we definitely get it.”
Surendran Chemmenkotil, page 13 of the filed PDF · View the filing
There was no price increase during the quarter; the realization growth came from TruHealth and Specialty mix.
Answered by Surendran Chemmenkotil
Asked by Samit Basak: Was the 5%-6% realization growth entirely driven by TruHealth and Specialty mix, or did price hikes contribute?
p. 15
“No, there is absolutely no price increase during this quarter. In fact, last time we increased the prices was January 2025.”
Surendran Chemmenkotil, page 15 of the filed PDF · View the filing
The 500 center expansion figure is a net number, and rationalization happens periodically, roughly every 18-24 months.
Answered by Surendran Chemmenkotil
Asked by Sudarshan Agarwal: Regarding center closures, is net addition of 500 centers the ongoing plan or will attrition continue?
p. 14
“The number that we are talking about, 500 center expansion, is a net number that we are talking about.”
Surendran Chemmenkotil, page 14 of the filed PDF · View the filing
Management said they prefer to stick to the 14%-15% guidance and not focus on quarter-by-quarter seasonality since business is influenced by unpredictable factors like weather.
Answered by Ameera Shah
Asked by Kunal Thanvi: Is the 14%-15% guidance conservative given recent quarters have exceeded it, or was this quarter a one-off?
p. 18
“I think we would like to stick to our guidance for 14%-15%, because, as you have seen over the last two quarters before this, we have been able to deliver that number.”
Ameera Shah, page 18 of the filed PDF · View the filing
TruHealth is already at company-level margins, while Core Diagnostics was at approximately 8% margin last quarter and is expected to reach 25% over three to four years post-acquisition.
Answered by Ameera Shah
Asked by Raman Venkata Kerti: What is the margin trajectory for Core Diagnostics and TruHealth versus the standalone Metropolis portfolio?
p. 21
“For example, at the end of the last quarter, we saw approximately 8% margin for Core.”
Ameera Shah, page 21 of the filed PDF · View the filing
No price increase was taken this year due to GST benefits being passed to consumers, but inflation will eventually need to be passed on.
Answered by Surendran Chemmenkotil
Asked by Tarun Bhatnagar: Is the industry more conducive to price increases, and what would determine a price increase decision?
p. 19
“This year, then we didn't do it for the reasons I mentioned. As we go forward, of course, part of the inflation will have to be passed on to the consumer.”
Surendran Chemmenkotil, page 19 of the filed PDF · View the filing
Risks flagged
Weather unpredictability affecting disease patterns and testing demand, making growth difficult to forecast
p. 18
“The reality is climate change is changing everything for everybody. Weathers are unpredictable and our business is heavily influenced by weather.”
Ameera Shah, page 18 of the filed PDF · View the filing
Lower margin profile of newly acquired Core Diagnostics business dragging on consolidated margins
p. 10
“This was achieved despite the relatively lower margin profile of Core Diagnostics and the impact of advancing annual employee increments from July to April this year.”
Surendran Chemmenkotil, page 10 of the filed PDF · View the filing
Cost inflation and geopolitical pressures on raw materials
p. 15
“Also, in the context of the ongoing geopolitical situation, RM pressures.”
Samit Basak, page 15 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.